1,25-Dihydroxyvitamin D3 mitigates high glucose-induced oxidative stress, inflammation, and extracellular matrix accumulation in glomerular mesangial cells via the ROS/TXNIP/NLRP3 pathway

Diabetic nephropathy (DN) is a leading cause of chronic kidney disease, driven partly by runaway oxidative stress and inflammation in the kidney's filtering cells. This laboratory study tested whether calcitriol — the active hormonal form of vitamin D (1,25-dihydroxyvitamin D3) — could protect glomerular mesangial cells from the damage caused by high blood sugar. Using cells bathed in high-glucose solution and a rat model of DN, the researchers showed that calcitriol disrupts a chain reaction that starts with reactive oxygen species (ROS), activates a regulatory protein called TXNIP, and ultimately triggers the NLRP3 inflammasome — a molecular alarm system that drives inflammation and a form of cell death called pyroptosis. By breaking this chain, calcitriol reduced inflammatory cytokines, lessened the build-up of scar-forming proteins (extracellular matrix), and improved markers of kidney function in rats. The antioxidant drug NAC was used as a comparator to confirm that ROS suppression is the critical upstream event. Overall, the findings support a mechanistic rationale for vitamin D as a renoprotective agent in DN, though all evidence remains at the preclinical stage.

• Calcitriol (tested across 1–50 nM in vitro) suppressed high glucose-induced ROS generation (measured by DCFH-DA fluorescence), reduced MDA content, and restored SOD activity in glomerular mesangial cells, confirming antioxidant efficacy at the cellular level.
• TXNIP protein expression and NLRP3 inflammasome components (NLRP3, ASC, caspase-1, IL-1β, IL-18) were downregulated by calcitriol treatment, paralleling the effect of the ROS scavenger NAC (10 mM), which established ROS as the upstream trigger of TXNIP/NLRP3 activation in this model.
• In DN rats, calcitriol ameliorated renal dysfunction (reduced serum creatinine, blood urea nitrogen, and 24-h urinary protein) and attenuated histopathological damage on PAS and Masson trichrome staining, while also lowering extracellular matrix proteins collagen IV, fibronectin, and laminin — indicating reduced fibrotic remodeling alongside anti-inflammatory effects.

This is a preclinical in-vitro and in-vivo study. Glomerular mesangial cells were exposed to high-glucose conditions and treated with calcitriol (1–50 nM) or NAC (10 mM) as a positive-control antioxidant; cell viability was confirmed by CCK-8 assay. Oxidative stress (ROS, MDA, SOD), pyroptosis (LDH release, PI/Hoechst staining), inflammatory cytokines (ELISA for IL-1β, IL-6, TNF-α, IL-18), ECM proteins (fibronectin, collagen IV, laminin), and pathway components (RT-qPCR, western blot, immunofluorescence) were quantified. A rat DN model provided in-vivo validation through renal function biochemistry and histopathology. Specific sample sizes (number of rats, passage number of cells, replication n) are not reported in the available abstract.

As a purely preclinical study using cell culture and a rodent DN model, these findings cannot be directly extrapolated to human diabetic nephropathy; species differences in vitamin D metabolism and NLRP3 regulation may limit translation. The dose range tested in vitro (1–50 nM calcitriol) exceeds typical physiological serum concentrations in humans, and no pharmacokinetic or safety data are provided. The study design does not include genetic knockdown (e.g., TXNIP siRNA or NLRP3 knockout) to formally prove pathway causality, so the hierarchy of ROS→TXNIP→NLRP3 is inferred partly from the NAC comparator. Future experiments should employ pathway-specific knockouts, test clinically achievable doses, and ultimately be validated in human kidney biopsy tissue or clinical biomarker studies.

This study extends the corpus's focus on NLRP3 inflammasome suppression as a therapeutic strategy across diverse disease contexts. It parallels [§45], which investigates oral NLRP3 inhibition with ruvonoflast in humans at elevated cardiovascular risk — the current article provides the upstream mechanistic detail (ROS→TXNIP→NLRP3) that clinical NLRP3-inhibitor trials largely assume but cannot isolate. It also parallels [§70], which examines tirzepatide's effects on chronic inflammation in people with HIV: both articles address metabolic-inflammatory crosstalk and cytokine burden (IL-1β, IL-6, TNF-α), but [§70] provides human-level evidence that the current preclinical study lacks. Together, these articles illustrate the translational gap between mechanistic in-vitro pathway dissection and clinical anti-inflammatory intervention — a gap that the preliminary tier rating of this article appropriately flags.

• Anti-inflammatory effects of oral NLRP3 inhibition with ruvonoflast among individuals at elevated cardiovascular risk
  Direct thematic complement: ruvonoflast targets NLRP3 pharmacologically in a clinical population, allowing readers to compare a validated human NLRP3-inhibition strategy with the upstream ROS/TXNIP mechanism characterized here.
• Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV
  Both studies measure overlapping inflammatory cytokines (IL-1β, IL-6, TNF-α) in metabolic disease contexts, but [id=70] offers a randomized human cohort, highlighting what clinical translation of the current preclinical findings would need to achieve.
• Effect of methotrexate on endothelial function in psoriasis patients
  Examines an anti-inflammatory intervention (methotrexate) and its effect on endothelial function in a chronic inflammatory condition, providing a contrast case for how preclinical mechanistic rationale does or does not predict vascular outcomes in clinical studies.